StockData
Silexion Therapeutics Corp logo

Silexion Therapeutics Corp (SLXN) stock

SLXNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as SLXNW
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 6/30
$1.44−0.21 (-12.73%)

Close on Nov 18, 2026Market cap $868.40KP/E –Yield –

Silexion Therapeutics cash

Cash and short-term investments held at the end of each period.

Silexion Therapeutics's cash was $4.76M at Sep 30, 2026. For fiscal 2025 it was $5.99M, up 371.7% from the year before.

Annual cash

PeriodPeriod endValueChange
FY2025Dec 31, 2025$5.99M+371.7%
FY2024Dec 31, 2024$1.27M-72.7%
FY2023Dec 31, 2023$4.65M-44.1%
FY2022Dec 31, 2022$8.31M–

Quarterly cash

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$4.76M-48.9%
Q2 FY2026Jun 30, 2026$2.32M-34.5%
Q1 FY2026Mar 31, 2026$2.50M-59.9%
Q4 FY2025Dec 31, 2025$5.99M+371.7%
Q3 FY2025Sep 30, 2025$9.32M+360.9%
Q2 FY2025Jun 30, 2025$3.54M+102.9%
Q1 FY2025Mar 31, 2025$6.23M+120.2%
Q4 FY2024Dec 31, 2024$1.27M-72.7%
Q3 FY2024Sep 30, 2024$2.02M-65.2%
Q2 FY2024Jun 30, 2024$1.75M-73.1%
Q1 FY2024Mar 31, 2024$2.83M-64.3%
Q4 FY2023Dec 31, 2023$4.65M-44.1%
Q3 FY2023Sep 30, 2023$5.81M–
Q2 FY2023Jun 30, 2023$6.49M–
Q1 FY2023Mar 31, 2023$7.92M–
Q4 FY2022Dec 31, 2022$8.31M–

More Silexion Therapeutics figures

See a number that looks wrong?